LBT-3627

LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) that can change the behavior of immune cells so they protect dopamine-producing cells rather than attacking them. The drug has the potential to be administered orally. The drug may one day help those with Parkinson's disease.

Function

LBT-3627 specifically targets the VIP₂ receptor, unlike VIP. The drug also affects microglia. In addition, LBT-3627 is more durable in the body compared to VIP.

History and development

Scientists at the University of Nebraska Medical Center and Longevity Biotech, Inc. first demonstrated the use of the drug in mouse models.

A phase I trial for humans is planned for 2017.

References